[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,439,592
  • Shares Outstanding, K 133,513
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 752 M
  • EBITDA $ 808 M
  • 60-Month Beta 0.27
  • Price/Sales 7.39
  • Price/Cash Flow 102.51
  • Price/Book 35.58

Options Overview Details

View History
  • Implied Volatility 51.90% (-3.52%)
  • Historical Volatility 101.60%
  • IV Percentile 91%
  • IV Rank 75.14%
  • IV High 59.29% on 07/27/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 20) 17.34 (8.44%)
  • Put/Call Vol Ratio 0.87
  • Today's Volume 3,550
  • Volume Avg (30-Day) 1,969
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 36,290
  • Open Int (30-Day) 30,762
  • Expected Range 188.18 to 222.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.71
  • Number of Estimates 8
  • High Estimate $2.83
  • Low Estimate $1.04
  • Prior Year $1.84
  • Growth Rate Est. (year over year) -7.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
197.81 +3.90%
on 07/30/26
380.00 -45.92%
on 07/09/26
-95.51 (-31.73%)
since 06/30/26
3-Month
197.81 +3.90%
on 07/30/26
380.00 -45.92%
on 07/09/26
-103.97 (-33.59%)
since 04/30/26
52-Week
197.81 +3.90%
on 07/30/26
495.55 -58.53%
on 10/20/25
-134.28 (-39.52%)
since 07/30/25

Most Recent Stories

More News
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam”...

ALNY : 205.52 (+0.02%)
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) on behalf of investors concerning...

ALNY : 205.52 (+0.02%)
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY ) investors concerning the Company’s...

ALNY : 205.52 (+0.02%)
Alnylam: Q2 Earnings Snapshot

Alnylam: Q2 Earnings Snapshot

ALNY : 205.52 (+0.02%)
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2...

ALNY : 205.52 (+0.02%)
Whether Alnylam's Guidance Can Justify Analysts Finally Turning Bullish After Years of Misses

Barchart Research What to Expect from ALNY Earnings ALNY Generated July 29, 2026 Current Price $286.62 EPS Estimate $$1.44 Consensus Rating Moderate Buy Average Move 6.38% Whether Alnylam's Guidance Can...

ALNY : 205.52 (+0.02%)
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday,...

ALNY : 205.52 (+0.02%)
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) − − Announces Completion of Enrollment in the...

ALNY : 205.52 (+0.02%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 169.64 (-0.99%)
ALNY : 205.52 (+0.02%)
IONS : 51.77 (-2.83%)
BBIO : 80.09 (-2.50%)
PFE : 25.01 (+0.40%)
Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures...

ALK : 47.45 (+0.44%)
SNDK : 1,214.83 (-5.09%)
FDXF : 140.53 (+2.17%)
PSKY : 7.96 (+1.92%)
STX : 856.13 (+0.52%)
WDC : 544.84 (+2.21%)
AMD : 476.15 (-1.90%)
UPS : 104.22 (-1.00%)
SPY : 747.03 (+0.72%)
MU : 823.03 (-5.90%)
ALNY : 205.52 (+0.02%)
AAL : 15.27 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 216.85
2nd Resistance Point 212.42
1st Resistance Point 208.97
Last Price 205.52
1st Support Level 201.09
2nd Support Level 196.66
3rd Support Level 193.21

See More

52-Week High 495.55
Fibonacci 61.8% 381.81
Fibonacci 50% 346.68
Fibonacci 38.2% 311.55
Last Price 205.52
52-Week Low 197.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.